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KEYWORDS	
	 2‐Substituted	 6‐(5‐oxo‐1‐phenylpyrrolidin‐3‐yl)pyrimidin‐4(3H)‐ones	 were	 synthesized	 in
three	 steps	 from	 itaconic	 acid	 derivatives	 via	 cyclization	with	 primary	 amines	 followed	 by
Masamune‐Claisen	 condensation,	 and	 cyclization	 of	 the	 newly	 formed	 β‐keto	 esters	 with
amidines.	Preparation	and/or	 isolation	of	β‐keto	esters	with	polar	N‐substituents	 failed,	but
the	corresponding	final	products	were	obtained	in	a	different	way.	6‐(1‐(3‐Hydroxypropyl)‐5‐
oxopyrrolidin‐3‐yl)‐2‐phenylpyrimidin‐4(3H)‐one	 was	 obtained	 by	 hydrogenolytic	 o‐
deprotection	of	its	o‐benzyl	derivative.	Depending	on	reaction	conditions,	further	mesylation
of	 6‐(1‐(3‐(benzyloxy)propyl)‐5‐oxopyrrolidin‐3‐yl)‐2‐phenylpyrimidin‐4(3H)‐one	 followed
by	treatment	with	pyrrolidine	gave	either	the	monoaminated‐	or	the	diaminated	product.	The
structures	of	novel	compounds	were	determined	by	NMR.	
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1.	Introduction	
	
Histamine,	dopamine,	tryptamine,	serotonin,	and	melatonin	
are	 representative	 chemical	messengers	playing	 a	 crucial	 role	
in	biological	processes	[1].	Various	2‐[(hetero)aryl]ethylamines	
are	 analogues	 of	 the	 above	 chemical	 messengers	 and,	
consequently,	 such	 2‐ethylamino‐functionalized	 heterocyclic	
compounds	 represent	 attractive	 synthetic	 targets.	 In	 this	
context,	 the	 preparation	 of	 novel	 synthetic	 analogues	 of	
naturally	occurring	2‐((hetero)aryl)ethylamines	is	of	particular	
interest	 in	 medicinal,	 synthetic	 organic,	 and	 combinatorial	
chemistry	[2‐9].	In	the	last	decade,	the	synthesis	of	aminoethyl	
functionalized	heterocycles	has	represented	an	important	part	
of	 our	 research	 studies.	Within	 this	 context,	we	 have	 been	 so	
far	 focused	 on	 the	 synthesis	 of	 two	 types	 of	 2‐(heteroaryl)	
ethylamines:	a)	the	open‐chain	analogues	of	histamine,	1,	 [10‐
13]	 and	 bicyclic	 conformationally	 constrained	 analogues	 of	
histamine,	 2‐4,	 [14‐16]	 and	 b)	 2‐substituted	 6‐(5‐oxo‐1‐
phenylpyrrolidin‐3‐yl)pyrimidine‐5‐carboxamides,	5,	as	2‐
aminoethyl‐functionalized	 pyrimidines	 [17].	 In	 continuation,	
we	 have	 focused	 our	 attention	 on	 2‐substituted	 6‐(5‐oxo‐1‐
phenylpyrrolidin‐3‐yl)pyrimidin‐4(3H)‐ones,	 6,	 as	 novel	 type	
of	2‐aminoethyl‐functionalized	pyrimidines	(Scheme	1).	
	
2.	Experimental	
	
[1,1'‐Biphenyl]‐4‐carboxamidine	 hydrochloride	 (11d),	 and	
4‐((pyrrolidin‐1‐yl)methyl)benzamidine	dihydrochloride	(11e)	
were	 purchased	 from	 Ukrorgsyntez	 Ltd.	 5‐Oxo‐1‐
phenylpyrrolidine‐3‐carboxylic	acid	(9a)	[18],	methyl	3‐oxo‐3‐
(5‐oxo‐1‐phenylpyrrolidin‐3‐yl)propanoate	 (10a)	 [16],	 and	 3‐
(benzyloxy)propylamine	(8b)	[19]	were	prepared	according	to	
the	literature	procedures.	All	other	compounds	were	purchased	
from	Sigma‐Aldrich.		
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2.1.	Instrumentation	
	
Melting	 points	 were	 determined	 on	 a	 Stanford	 Research	
Systems	 MPA100	 OptiMelt	 automated	 melting	 point	 system.	
The	NMR	spectra	were	obtained	on	a	Bruker	Avance	DPX	300	
at	 300	 MHz	 for	 1H	 and	 75.5	 MHz	 for	 13C	 nucleus.	 All	 NMR	
measurements	 were	 performed	 with	 TMS	 as	 the	 internal	
standard.	 Mass	 spectra	 were	 recorded	 on	 an	 Agilent	 6224	
Accurate	 Mass	 TOF	 LC/MS	 spectrometer.	 IR	 spectra	 were	
recorded	on	a	Perkin‐Elmer	Spectrum	BX	FT‐IR	spectrophoto‐
meter.	 Microwave	 irradiations	 were	 performed	 on	 CEM	
Discover	 Laboratory	 Microwave	 Oven.	 Microanalyses	 were	
performed	 on	 a	 Perkin‐Elmer	 CHN	 Analyzer	 2400	 II	 on	 the	
Faculty	 of	 Chemistry	 and	 Chemical	 Technology,	 University	 of	
Ljubljana.	 Flash	 column	 chromatography	 (FC)	 and	 column	
chromatography	 (CC)	 were	 performed	 on	 silica	 gel	 (Fluka,	
Silica	gel	60,	particle	 size	0.035‐0.070	mm).	Medium	pressure	
liquid	 chromatography	 (MPLC)	 was	 performed	 on	 a	 Büchi	
Flash	Chromatography	System	(Büchi	Fraction	Collector	C‐660,	
Büchi	Pump	Module	C‐605,	Büchi	Control	Unit	C‐620)	on	silica	
gel	 (LiChroprep®	 Si	 60,	 15‐25	 µm),	 column	 dimensions:	
26×460	mm,	backpressure:	10	Bar,	detection:	UV	(254	nm).	
	
2.2.	Synthesis	
	
2.2.1.	Synthesis	of	1‐(3‐(substituted)propyl)‐5‐
oxopyrrolidine‐3‐carboxylic	acids	(9c,d)	
	
Compounds	9c	 and	9d	were	 prepared	 following	modified	
literature	procedure	[18].	A	mixture	of	itaconic	acid	(7a)	(1.30	
g,	10	mmol),	water	(4	mL),	and	3‐amino‐1‐propanol	(8c)	(751	
mg,	10	mmol)	or	 3‐(dimethylamino)propanamine	 (8d)	 (1.021	
g,	 10	mmol)	 was	 heated	 in	 a	 sealed	 vessel	 under	 microwave	
irradiation	 (300	 W,	 120	 °C,	 ~3	 bar)	 for	 1	 h.	 The	 reaction	
mixture	was	evaporated	in	vacuum	and	the	residual	water	was	
removed	 by	 repetitive	 co‐evaporation	 in	 vacuum	 with	 ethyl	
acetate	(3×20	mL)	and	dichloromethane	(3×20	mL)	to	give	the	
crude	 oily	 compounds	 9c	 and	 9d,	 which	 were	 used	 in	 the	
following	step	without	purification	(Scheme	2).	
1‐(3‐(Hydroxy)propyl)‐5‐oxopyrrolidine‐3‐carboxylic	 acid	
(9c):	Yield:	100%	of	brownish	oil.	1H	NMR	(300	MHz,	DMSO‐d6,	
δ,	ppm):	1.57	(p,	2H,	J	=	6.8	Hz,	CH2CH2CH2),	2.38‐2.43	(m,	2H,	
4‐CH2),	 2.93‐3.04	 (m,	 1H,	 3‐H),	 3.19	 (dt,	 2H,	 J	 =	 4.0,	 7.1	 Hz,	
CH2CH2CH2N),	 3.37	 (t,	 2H,	 J	 =	 6.3	Hz,	 CH2CH2CH2O),	 3.44‐3.50	
(m,	2H,	2‐CH2),	OH	and	COOH	exchanged.	
1‐(3‐(Dimethylamino)propyl)‐5‐oxopyrrolidine‐3‐carboxylic	
acid	 (9d):	 Yield:	 100%	 of	 brownish	 oil.	 1H	 NMR	 (300	 MHz,	
DMSO‐d6,	δ,	ppm):	1.60	(p,	2H,	J	=	7.2	Hz,	CH2CH2CH2),	2.21	(s,	
6H,	 NMe2),	 2.26‐2.34	 (m,	 2H,	 CH2CH2CH2NMe2),	 2.38‐2.44	 (m,	
2H,	 4‐CH2),	 2.95‐3.06	 (m,	 1H,	 3‐H),	 3.09‐3.24	 (m,	 2H,	
CH2CH2CH2N),	3.44‐3.50	(m,	2H,	2‐CH2),	COOH	exchanged.	
	
2.2.2.	Synthesis	of	methyl	1‐(3‐(benzyloxy)propyl)‐5‐
oxopyrrolidine‐3‐carboxylate	(12)		
	
This	compound	was	prepared	following	a	slightly	modified	
literature	procedure	[20].	A	solution	of	3‐(benzyloxy)propan‐1‐
amine	(8b)	(2.484	g,	15	mmol)	in	methanol	(20	mL)	was	added	
drop	 wise	 to	 a	 stirred	 solution	 of	 dimethyl	 itaconate	 (7b)	
(2.378	g,	15	mmol)	in	methanol	(70	mL)	at	room	temperature	
(r.t.)	 and	 the	mixture	was	 stirred	 at	 r.t.	 for	 24	 h.	 The	 solvent	
was	 removed	 in	vacuum	to	give	 the	crude	oily	12,	which	was	
used	in	the	following	step	without	further	purification	(Scheme	
2).	Yield:	100%	of	yellowish	oil.	FT‐IR	(KBr,	cm‐1):	3029	(CH)	
(br,	alkyl),	2948	(CH)	(br,	alkyl),	2860	(CH)	(br,	alkyl),	1733	
(C=O)	 (ester),	 1683	 (C=O)	 (br,	 amide),	 1493,	 1452,	 1434,	
1362,	1265,	1199,	1178,	1098,	1026,	937,	848,	737,	698,	609.	
1H	NMR	(CDCl3,	300	MHz,	δ,	ppm):	1.84	(tt,	2H,	J	=	7.2,	6.1	Hz,	
CH2CH2CH2),	2.61	(dd,	1H,	J	=	17.1,	9.6	Hz,	4‐Ha),	2.68	(dd,	1H,	J	
=	17.1,	7.6	Hz,	4‐Hb),	3.12‐3.24	 (m,	1H,	3‐H),	3.40	 (td,	2H,	 J	 =	
2.7;	7.0	Hz,	CH2CH2CH2N),	3.50	(t,	2H,	J	=	6.2	Hz,	CH2CH2CH2O),	
3.55‐3.65	 (m,	 2H,	 2‐CH2),	 3.73	 (s,	 3H,	 CO2Me),	 4.49	 (s,	 2H,	
PhCH2O),	 7.27‐7.38	 (m,	5H,	Ph).	 13C	NMR	 (CDCl3,	 75.5	MHz,	 δ,	
ppm):	27.0,	33.5,	35.4,	39.4,	48.6,	51.7,	67.2,	72.4,	127.0,	127.1,	
127.8,	137.9,	171.7,	172.7.	HRMS	(EI):	m/z	found	for	C16H21NO4:	
m/z	=	292.1544	(MH+);	calcd.:	m/z	=	292.1549	(MH+).	
	
2.2.3.	Synthesis	of	1‐(3‐(Benzyloxy)propyl)‐5‐oxopyrrolidine‐
3‐carboxylic	acid	(9b)	
	
LiOH·H2O	(839	mg,	20	mmol)	was	added	to	a	solution	of	the	
ester	12	from	the	above	experiment	(15	mmol)	in	a	mixture	of	
THF	 (7	 mL),	 H2O	 (7	 mL),	 and	 MeOH	 (7	 mL).	 The	 resulting	
mixture	 was	 stirred	 at	 r.t.	 for	 1	 h.	 MeOH	 and	 THF	 were	
removed	 by	 evaporation	 in	 vacuum	 at	 50	 mbar/35	 oC,	 the	
aqueous	 residue	 was	 diluted	 with	 H2O	 (20	 mL),	 and	 washed	
with	CH2Cl2	(3×100	mL).	The	aqueous	phase	was	acidified	with	
aq.	HCl	(1M,	22	mL)	and	the	product	was	extracted	with	EtOAc	
(3×100	mL).	The	combined	organic	phase	was	dried	over	anh.	
Na2SO4,	 filtered,	 and	 the	 filtrate	was	evaporated	 in	vacuum	 to	
give	compound	9b	(Scheme	2).	Yield:	87%	of	yellowish	oil.	FT‐
IR	(NaCl,	cm‐1):	2926	(CH)	(alkyl),	1731	(C=O)	(ester),	1650	
(C=O)	 (amide),	 1496,	 1454,	 1366,	 1199,	 1105,	 745,	 700.	 1H	
NMR	 (CDCl3,	 300	 MHz,	 δ,	 ppm):	 1.84	 (p,	 2H,	 J	 =	 6.9	 Hz,	
CH2CH2CH2),	2.67	(dd,	1H,	J	=	17.3,	9.7	Hz,	4'‐Ha),	2.75	(dd,	1H,	J	
=	17.2,	7.2	Hz,	4'‐Hb),	3.11‐3.27	(m,	1H,	3'‐H),	3.41	(td,	2H,	 J	=	
7.2,	2.5	Hz,	CH2CH2CH2N),	3.50	(t,	2H,	J	=	6.1	Hz,	CH2CH2CH2O),	
3.58	(dd,	1H,	J	=	10.1,	8.5	Hz,	2'‐Ha),	3.66	(dd,	1H,	J	=	10.1,	6.1	
Hz,	 2'‐Hb),	 4.48	 (s,	 2H,	 PhCH2O),	 6.91	 (br	 s,	 1H,	 COOH),	 7.23‐
7.43	(m,	5H,	Ph).	13C	NMR	(CDCl3,	75.5	MHz):	δ	27.4,	34.2,	36.0,	
40.4,	49.6,	67.7,	73.1,	 127.8,	127.9,	128.5,	138.2,	173.9,	175.7.	
HRMS	 (EI):	m/z	 found	 for	 C15H19NO4:	 278.1379	 (MH+);	 calcd.:	
m/z	=	278.1392	(MH+).	
	
2.2.4.	Synthesis	of	methyl	3‐(1‐(3‐(benzyloxy)propyl)‐5‐
oxopyrrolidin‐3‐yl)‐3‐oxopropanoate	(10b)	
	
This	 compound	 was	 prepared	 following	 the	 literature	
procedure	for	the	synthesis	of	closely	related	compounds	[2,3].	
Under	 argon,	 1,1'‐carbonyldiimidazole	 (CDI)	 (2.69	 g,	 16.59	
mmol)	 was	 added	 to	 a	 stirred	 solution	 of	 carboxylic	 acid	 9b	
(3.63	g,	13.1	mmol)	in	anh.	THF	(60	mL)	at	r.t.	and	the	resulting	
mixture	was	stirred	at	r.t.	for	1	h.	During	this	time	CO2	evolved,	
therefore	the	reaction	flask	was	not	completely	sealed.	A	solid	
powdered	 mixture	 of	 MgCl2	 (1.21	 g,	 12.71	 mmol)	 and	
potassium	 monomethyl	 malonate	 (3.07	 g,	 19.65	 mmol)	 was	
added	 under	 a	 blanket	 of	 argon	 in	 one	 portion	 via	 a	 powder	
funnel,	which	was	then	rinsed	with	anh.	THF	(20	mL),	and	the	
resulting	 suspension	was	 stirred	 under	 argon	 at	 r.t.	 for	 12	 h.	
Volatile	 components	were	 evaporated	 in	 vacuum,	 aq.	 NaHSO4	
(1M,	100	mL)	was	added	 to	 the	 residue,	 and	 the	product	was	
extracted	with	EtOAc	(3×100	mL).	The	combined	organic	phase	
was	dried	over	anhydrous	Na2SO4,	filtered,	and	the	filtrate	were	
evaporated	in	vacuum	and	the	crude	oily	reside	was	purified	by	
CC	 (EtOAc).	 Fractions	 containing	 the	 product	 were	 combined	
and	 volatile	 components	 were	 evaporated	 in	 vacuum	 to	 give	
compound	10b	(Scheme	2).	Yield:	3.50	g	(80%)	of	yellowish	oil.	
FT‐IR	 (NaCl,	 cm‐1):	 2952	 (CH)	 (alkyl),	 2866	 (CH)	 (alkyl),	
1747	 (C=O)	 (ester),	 1715	 (C=O)	 (ketone),	 1682	 (C=O)	
(amide),	1495,	1454,	1362,	1317,	1268,	1100,	1027,	743,	700.	
1H	NMR	(CDCl3,	300	MHz,	δ,	ppm):	1.85	(p,	2H,	 J	=	7.0,	6.6	Hz,	
CH2CH2CH2),	2.50‐2.72	(m,	2H,	4'‐CH2),	3.36‐3.45	(m,	1H,	3'‐H),	
3.40	 (td,	 2H,	 J	 =	 7.0,	 2.0	 Hz,	 CH2CH2CH2N),	 3.46‐3.54	 (m,	 5H,	
CH2CH2CH2O,	CH2COOMe,	and	2'‐Ha),	3.64	 (dd,	1H,	 J	 =	9.5,	5.9	
Hz,	2'‐Hb),	3.75	(s,	3H,	COOMe),	4.48	(s,	2H,	PhCH2O),	7.23‐7.40	
(m,	5H,	Ph).	13C	NMR	(CDCl3,	75.5	MHz,	δ,	ppm):	27.4,	33.3,	40.2,	
42.9,	 47.5,	 47.9,	 52.5,	 67.8,	 73.1,	 127.6,	 127.7,	 128.4,	 138.3,	
167.0,	171.9,	200.9.	HRMS	(EI):	m/z	found	for	C18H23NO5:	m/z	=	
334.1658	(MH+);	calcd.:	m/z	=	334.1654	(MH+).	
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2.2.5.	General	procedure	for	the	synthesis	of	2‐substituted	6‐
(5‐oxo‐1‐phenylpyrrolidin‐3‐yl)pyrimidin‐4(3H)‐ones	(6a‐f)	
	
A	mixture	 of	 β‐keto	 ester	10a,b	 (1	mmol),	MeOH	 (4	mL),	
amidine	 salt	11a‐e	 (1	mmol),	 and	 KOBu‐t	 (112	mg,	 1	mmol)	
was	stirred	at	r.t.	 for	48	h.	Then,	water	(4	mL)	was	added,	the	
mixture	 was	 stirred	 at	 r.t.	 for	 1	 h,	 and	 the	 precipitate	 was	
collected	by	 filtration	 to	give	6a‐f.	 In	 this	manner,	analytically	
pure	compounds	6a‐d	were	obtained	(Scheme	2).	Compounds	
6e	and	6f	were	further	purified	by	FC	over	silica	gel	(d	=	3	cm,	l	
=	5	cm).	Fractions	containing	the	product	were	combined	and	
evaporated	in	vacuo	to	give	compound	6e	and	6f	(Scheme	2).	
6‐(5‐Oxo‐1‐phenylpyrrolidin‐3‐yl)pyrimidin‐4(3H)‐one	 (6a):	
Prepared	 from	 10a	 (261	 mg,	 1	 mmol),	 formamidine	 acetate	
(11a)	(104	mg,	1	mmol),	and	KOBu‐t	(112	mg,	1	mmol).	White.	
Yield:	33%.	M.p.:	223‐228	oC	(with	slow	decomp.	above	200	oC).	
FT‐IR	(KBr,	cm‐1):	2794	(OH)	(br,	alkyl),	1682	(C=O)	(amide),	
1662	 (C=O)	 (amide),	 1601,	 1500,	 1488,	 1458,	 1427,	 1398,	
1307,	 1283,	 1242,	 1221,	 1203,	 1176,	 1147,	 1118,	 1022,	 979,	
946,	916,	896,	877,	805,	773,	752,	721,	685,	661.	1H	NMR	(300	
MHz,	DMSO‐d6,	 δ,	 ppm):	2.70	 (dd,	1H,	 J	 =	16.8,	7.7	Hz,	4'‐Ha),	
2.85	(dd,	1H,	J	=	16.8,	9.0	Hz,	4'‐Hb),	3.60	(p,	1H,	J	=	8.1	Hz,	3'‐
H),	3.88	(dd,	1H,	J	=	9.8,	6.5	Hz,	2'‐Ha),	4.13	(t,	1H,	J	=	9.1	Hz,	2'‐
Hb),	6.32	(s,	1H,	5‐H),	7.13	(t,	1H,	J	=	7.3	Hz,	p‐Ph),	7.37	(t,	2H,	J	
=	7.8	Hz,	m‐Ph),	7.66	(d,	2H,	J	=	8.0	Hz,	o‐Ph),	8.19	(s,	1H,	2‐H),	
12.44	(s,	1H,	NH).	13C	NMR	(75.5	MHz,	DMSO‐d6,	δ,	ppm):	36.7,	
37.3,	52.0,	112.3,	119.4,	124.0,	128.7,	139.3,	150.4,	161.2,	167.0,	
172.3.	Anal.	 calcd.	 for	C14H13N3O2∙1¼H2O:	C,	55.89;	H,	4.77;	N,	
13.97.	Found:	C,	55.82;	H,	4.47;	N,	13.68%.	
2‐Methyl‐6‐(5‐oxo‐1‐phenylpyrrolidin‐3‐yl)pyrimidin‐4(3H)‐
one	 (6b):	 Prepared	 from	10a	 (261	mg,	 1	mmol),	 acetamidine	
hydrochloride	 (11b)(95	mg,	1	mmol),	 and	KOBu‐t	 (112	mg,	1	
mmol).	White.	Yield:	49%.	M.p.:	234‐237	oC.	FT‐IR	(KBr,	cm‐1):	
2986	(CH)	 (br,	 alkyl),	 1670	(C=O)	 (br,	 amide),	 1591,	 1497,	
1474,	1450,	1410,	1386,	1355,	1305,	1280,	1230,	1212,	1176,	
1128,	1048,	1017,	955,	888,	847,	752,	697,	684,	663.	 1H	NMR	
(300	MHz,	DMSO‐d6,	δ,	ppm):	2.28	(s,	3H,	2‐Me),	2.72	(dd,	1H,	J	
=	16.8,	8.4	Hz,	4'‐Ha),	2.81	(dd,	1H,	J	=	16.9,	9.0	Hz,	4'‐Hb),	3.55	
(qd,	1H,	J	=	8.5,	6.9	Hz,	3'‐H),	3.88	(dd,	1H,	J	=	9.7,	7.0	Hz,	2'‐Ha),	
4.10	(dd,	1H,	J	=	9.7,	8.4	Hz,	2'‐Hb),	6.16	(s,	1H,	5‐H),	7.03‐7.22	
(m,	1H,	p‐Ph),	7.28‐7.45	(m,	2H,	m‐Ph),	7.60‐7.76	(m,	2H,	o‐Ph),	
12.38	(s,	1H,	NH).	13C	NMR	(75.5	MHz,	DMSO‐d6,	δ,	ppm):	21.3,	
36.9,	37.2,	52.0,	109.2,	119.4,	124.0,	128.7,	139.3,	159.7,	162.4,	
166.7,	 172.3.	 Anal.	 calcd.	 for	 C15H15N3O2:	 C,	 66.90;	 H,	 5.61;	 N,	
15.60.	Found:	C,	66.60;	H,	5.54;	N,	15.38%.	
6‐(5‐Oxo‐1‐phenylpyrrolidin‐3‐yl)‐2‐phenylpyrimidin‐4(3H)‐
one	 (6c):	Prepared	 from	10a	 (261	mg,	1	mmol),	 benzamidine	
hydrochloride	(11c)(157	mg,	1	mmol),	and	KOBu‐t	(112	mg,	1	
mmol).	Yield:	72%	of	white	solid.	M.p.:	235‐236	oC.	FT‐IR	(KBr,	
cm‐1):	 3065	 (CH)	 (br,	 alkyl),	 1684	 (C=O)	 (amide),	 1685	
(C=O)	 (amide),	 1597,	 1542,	 1497,	 1471,	 1444,	 1389,	 1348,	
1301,	1281,	1228,	1180,	1126,	1034,	982,	925,	857,	792,	757,	
688,	669,	660,	641,	615.	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	
2.82	(dd,	1H,	J	=	16.3,	7.4	Hz,	4'‐Ha),	2.90	(dd,	1H,	J	=	16.2,	8.0	
Hz,	4‐Hb),	3.69	(qd,	1H,	 J	=	8.2,	6.5	Hz,	3'‐H),	3.98	(dd,	1H,	 J	=	
9.8,	6.5	Hz,	2'‐Ha),	4.20	(dd,	1H,	J	=	9.8,	8.2	Hz,	2'‐Hb),	6.36	(s,	
1H,	5‐H),	7.05‐7.20	(m,	1H,	p‐Ph),	7.38	(dd,	2H,	J	=	8.6,	7.3	Hz,	
m‐Ph),	7.47‐7.61	(m,	3H,	p‐Ph	and	m‐Ph),	7.66‐7.72	(m,	2H,	o‐
Ph),	8.11‐8.17	(m,	2H,	o‐Ph),	12.65	(s,	1H,	NH).	 13C	NMR	(75.5	
MHz,	 DMSO‐d6,	 δ,	 ppm):	 37.1,	 37.4,	 52.3,	 109.6,	 119.5,	 124.0,	
127.9,	 128.6,	 128.7,	 131.8,	 132.5,	 139.4,	 157.8,	 163.6,	 167.2,	
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172.4.	 Anal.	 calcd.	 for	 C20H17N3O2:	 C,	 72.49;	 H,	 5.17;	 N,	 12.68.	
Found:	C,	72.16;	H,	5.01;	N,	12.54%.	
2‐([1,1'‐Biphenyl]‐4‐yl)‐6‐(5‐oxo‐1‐phenylpyrrolidin‐3‐yl)	
pyrimidin‐4(3H)‐one	 (6d):	 Prepared	 from	 10a	 (261	 mg,	 1	
mmol),	 [1,1'‐biphenyl]‐4‐carboxamidine	 hydrochloride	
(11d)(232	mg,	1	mmol),	and	KOBu‐t	(112	mg,	1	mmol).	Yield:	
72%	of	white	 solid.	M.p.:	 303‐308	 oC.	FT‐IR	 (KBr,	 cm‐1):	 2877	
(CH)	 (br,	 alkyl),	1693	(C=O)	 (amide),	1649	(C=O)	 (amide),	
1594,	1542,	1519,	1491,	1384,	1356,	1296,	1281,	1223,	1187,	
1128,	1040,	1008,	980,	m900,	847,	756,	732,	688,	674.	1H	NMR	
(300	MHz,	DMSO‐d6,	δ,	ppm):	2.85	(dd,	1H,	J	=	16.8,	7.9	Hz,	4'‐
Ha),	2.91	(dd,	1H,	J	=	16.7,	8.8	Hz,	4'‐Hb),	3.70	(p,	1H,	J	=	7.8	Hz,	
3'‐H),	4.00	(dd,	1H,	J	=	9.6,	6.5	Hz,	2'‐Ha),	4.21	(dd,	1H,	J	=	9.7,	
8.2	Hz,	2'‐Hb),	6.37	 (s,	1H,	5‐H),	7.14	 (t,	1H,	 J	 =	7.3	Hz,	p‐Ph),	
7.35‐7.45	 (m,	3H,	m,p‐Ph),	 7.50	 (t,	 2H,	 J	 =	 7.7	Hz,	m‐Ph),	 7.71	
(dd,	2H,	 J	=	8.3,	1.3	Hz,	m‐C6H4),	7.75	(d,	2H,	 J	=	7.3	Hz,	o‐Ph),	
7.82	 (d,	 2H,	 J	 =	8.5	Hz,	o‐C6H4),	 8.25	 (d,	 2H,	 J	 =	8.0	Hz,	o‐Ph),	
12.76	(s,	1H,	NH).	13C	NMR	(75.5	MHz,	DMSO‐d6,	δ,	ppm):	37.1,	
37.3,	52.3,	119.4,	123.8,	126.6,	126.7,	127.9,	128.3,	128.5,	128.8,	
139.0,	139.2,	172.1.	Anal.	calcd.	for	C26H21N3O2·⅓H2O:	C,	75.53;	
H,	5.28;	N,	10.16.	Found:	C,	75.82;	H,	5.23;	N,	10.16%.	
6‐(5‐Oxo‐1‐phenylpyrrolidin‐3‐yl)‐2‐(4‐((pyrrolidin‐1‐yl)	
methyl)phenyl)pyrimidin‐4(3H)‐one	 (6e):	 Prepared	 from	 10a	
(261	 mg,	 1	 mmol),	 4‐((pyrrolidin‐1‐yl)methyl)benzamidine	
dihydrochloride	(11e)(232	mg,	1	mmol),	and	KOBu‐t	(224	mg,	
2	mmol);	flash	chromatography	(FC)	first	EtOAc:EtOH	=	10:1	to	
elute	 less	polar	 impurities,	then	EtOAc:EtOH	=	3:1	to	elute	the	
product	 6e.	 Yield:	 37%	 of	 yellowish	 solid.	 M.p.:	 202‐214	 oC	
(with	 slow	 decomp.	 above	 200	 oC).	 FT‐IR	 (KBr,	 cm‐1):	 2954	
(br,	 CH)	 (alkyl),	 2772	 (CH)	 (alkyl),	 1690	 (C=O)	 (amide),	
1651	 (C=O)	 (amide),	 1594,	 1541,	 1514,	 1495,	 1476,	 1421,	
1386,	1358,	1299,	1280,	1219,	1186,	1127,	1042,	981,	861,	756,	
690,	673,	661.	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):1.64‐1.76	
(m,	 4H,	 2×CH2	 of	 pyrrolidine),	 2.40‐2.52	 (m,	 4H,	 2×CH2	 of	
pyrrolidine),	2.82	(dd,	1H,	J	=	16.7,	7.8	Hz,	4'‐Ha),	2.90	(dd,	1H,	J	
=	16.7,	8.6	Hz,	4'‐Hb),	3.65	(s,	2H,	ArCH2N),	3.66	(p,	1H,	J	=	8.1	
Hz,	3'‐H),	3.97	(dd,	1H,	J	=	9.7,	6.5	Hz,	2'‐Ha),	4.19	(dd,	1H,	J	=	
9.8,	8.2	Hz,	2'‐Hb),	6.33	(s,	1H,	5‐H),	7.13	(t,	1H,	 J	=	7.4	Hz,	p‐
Ph),	7.38	(dd,	2H,	J	=	8.7,	7.2	Hz,	m‐Ph),	7.43	(d,	2H,	J	=	8.2	Hz,	
m‐C6H4),	7.70	(dd,	2H,	J	=	8.7,	7.2	Hz,	o‐Ph),	8.09	(d,	2H,	J	=	8.3	
Hz,	o‐C6H4),	12.56	(s,	1H,	NH).	13C	NMR	(DMSO‐d6,	75.5	MHz,	δ,	
ppm):	 23.1,	 37.1,	 37.4,	 52.3,	 53.5,	 59.0,	 109.2,	 119.5,	 124.0,	
127.8,	 128.6,	 128.7,	 131.3,	 139.4,	 143.1,	 157.8,	 163.9,	 167.1,	
172.4.	 Anal.	 calcd.	 for	 C25H26N4O2·H2O:	 C,	 69.42;	 H,	 6.53;	 N,	
12.95.	Found:	C,	69.37;	H,	6.31;	N,	12.97%.	
6‐(1‐(3‐(Benzyloxy)propyl)‐5‐oxopyrrolidin‐3‐yl)‐2‐phenyl	
pyrimidin‐4(3H)‐one	 (6f):	 Prepared	 from	 10b	 (261	 mg,	 1	
mmol),	 benzamidine	 hydrochloride	 (11c)(157	 mg,	 1	 mmol),	
and	KOBu‐t	(112	mg,	1	mmol);	FC	first	EtOAc	to	elute	less	polar	
impurities,	 then	 EtOAc:MeOH	 =	 10:1	 to	 elute	 the	 product	 6f.	
Yield:	 58%	 of	 yellowish	 oil.	 FT‐IR	 (NaCl,	 cm‐1):	 3063	 (CH)	
(NH)	 (alkyl,	 lactam),	 2928	 (CH)	 (NH)	 (alkyl,	 lactam),	 2861	
(CH)	 (NH)	 (alkyl,	 lactam),	 1657(C=O)	 (amide),	 1603,	 1548,	
1502,	 1444,	 1310,	 1265,	 1102,	 982,	 850,	 697.	 1H	 NMR	 (300	
MHz,	 DMSO‐d6,	 δ,	 ppm):	 1.89	 (p,	 2H,	 J	 =	 6.5	 Hz,	 CH2CH2CH2),	
2.71	(dd,	1H,	J	=	16.7,	9.0	Hz,	4'‐Ha),	2.81	(dd,	1H,	J	=	16.8,	7.8	
Hz,	 4'‐Hb),	 3.41‐3.50	 (m,	 1H,	 3'‐H),	 3.46	 (t,	 2H,	 J	 =	 7.1	 Hz,	
CH2CH2CH2N),	 3.52	 (t,	 2H,	 J	 =	 6.2	 Hz,	 CH2CH2CH2O),	 3.59	 (dd,	
1H,	 J	=	9.6,	6.5	Hz,	2'‐Ha),	3.71	(dd,	1H,	 J	=	9.6,	8.5	Hz,	2'‐Hb),	
4.46	 (s,	2H,	PhCH2O),	6.29	 (s,	 1H,	5‐H),	7.20‐7.34	 (m,	 5H,	Ph),	
7.49‐7.61	(m,	3H,	m,p‐Ph),	8.16‐8.22	(m,	2H,	o‐Ph),	12.73	(s,	1H,	
NH).	 13C	 NMR	 (75.5	MHz,	 DMSO‐d6,	 δ,	 ppm):	 27.7,	 36.4,	 38.5,	
40.1,	51.8,	 67.8,	73.1,	110.1,	127.6,	127.7,	127.9,	128.4,	129.0,	
131.8,	132.3,	138.3,	157.4,	165.3,	168.6,	173.4.	HRMS	(EI):	m/z	
found	 for	 C24H25N3O3:	 m/z	 =	 404.1967	 (MH+);	 calcd.:	 m/z	 =	
404.1974	(MH+).	
	
2.2.6.	Synthesis	of	6‐(1‐(3‐hydroxypropyl)‐5‐oxopyrrolidin‐3‐
yl)‐2‐phenylpyrimidin‐4(3H)‐one	(6g)	
	
A	mixture	of	6f	(1	g,	2.48	mmol),	MeOH	(100	mL),	and	10%	
Pd‐C	(350	mg)	was	hydrogenated	(P	=	60	psi	of	H2)	at	50	°C	for	
7	 days.	 The	 reaction	 mixture	 was	 filtered	 through	 a	 plug	 of	
Celite®	 and	 thoroughly	 washed	 with	 CH2Cl2.	 Volatile	
components	were	 evaporated	 in	vacuum	and	 the	 residue	was	
purified	 by	 CC	 (EtOAc:MeOH;	 10:1).	 Fractions	 containing	 the	
product	 were	 combined	 and	 volatile	 components	 were	
evaporated	 in	 vacuum	 to	 give	 compound	 6g.	 Yield:	 471	 mg	
(60%)	 of	 white	 semi‐solid.	 FT‐IR	 (KBr,	 cm‐1):	 3425	 (OH)	
(alcohol),	 2934	 (CH)	 (NH)	 (alkyl,	 lactam),	 1652	 (C=O)	
(amide),	1550,	1496,	1444,	1401,	1308,	1269,	1179,	1058,	983,	
853,	756,	694.	1H	NMR	(300	MHz,	CDCl3,	δ,	ppm):	1.74	(p,	2H,	J	
=	6.0	Hz,	CH2CH2CH2),	2.80	(dd,	1H,	J	=	17.0,	8.9	Hz,	4'‐Ha),	2.88	
(dd,	 1H,	 J	 =	 16.9,	 7.3	Hz,	 4'‐Hb),	 3.32‐3.44	 (m,	 1H,	 3'‐H),	 3.44	
(dt,	1H,	J	=	14.1,	5.9	Hz,	1H	of	CH2CH2CH2N),	3.52‐3.67	(m,	5H,	
1H	of	CH2CH2CH2N,	CH2CH2CH2OH,	and	2'‐Ha),	3.74	(dd,	1H,	J	=	
9.5,	8.5	Hz,	2'‐Hb),	6.32	(s,	1H,	5‐H),	7.51‐7.63	(m,	3H,	m,p‐Ph),	
8.11‐8.17	 (m,	 2H,	 o‐Ph),	 12.15	 (br	 s,	 1H,	 NH).	 13C	 NMR	 (75.5	
MHz,	DMSO‐d6,	δ,	ppm):	29.6,	36.2,	38.2,	39.1,	51.8,	58.5,	110.0,	
127.7,	 128.8,	 131.6,	 132.2,	 157.4,	 165.0,	 168.2,	 174.3.	 HRMS	
(EI):	m/z	 found	for	C17H19N3O3:	m/z	=	314.1499	(MH+);	calcd.:	
m/z	=	314.1505	(MH+).	
	
2.2.7.	Synthesis	of	3‐(4‐(6‐((methylsulfonyl)oxy)‐2‐phenyl‐
pyrimidin‐4‐yl)‐2‐oxopyrrolidin‐1‐yl)propyl	methane	
sulfonate	(13)	
	
To	 a	 cooled	 (‐5	 °C)	 stirred	 solution	of	 compound	6g	 (250	
mg,	0.80	mmol)	in	anh.	CH2Cl2	(5	mL)	was	added	anh.	Et3N	(280	
µL,	2	mmol)	 followed	by	addition	of	methanesulfonyl	chloride	
(131	µL,	1.7	mmol)	and	the	resulting	mixture	was	stirred	at	‐5	
°C	for	20	min.	and	at	r.t.	for	30	min.	The	reaction	mixture	was	
directly	(without	previous	evaporation)	purified	by	FC	(EtOAc).	
Fractions	 containing	 the	 product	 were	 combined	 and	 volatile	
components	were	evaporated	in	vacuum	to	give	compound	13	
(Scheme	 3).	 Yield:	 326	 mg	 (86%)	 of	 white	 semi‐solid.	 FT‐IR	
(KBr,	 cm‐1):	 2936	 (CH)	 (alkyl),	 1682	 (C=O)	 (amide),	 1592,	
1574,	1556,	1496,	1370,	1317,	1190,	1040,	929,	802,	776,	701.	
1H	 NMR	 (300	 MHz,	 CDCl3,	 δ,	 ppm):	 2.02	 (p,	 2H,	 J	 =	 6.4	 Hz,	
CH2CH2CH2),	 2.83	 (d,	 2H,	 J	 =	 7.7	 Hz,	 4'‐CH2),	 3.00	 (s,	 3H,	
NSO2Me),	 3.48	 (t,	 2H,	 J	 =	 6.8	 Hz,	 CH2CH2CH2N),	 3.65	 (s,	 3H,	
OSO2Me),	3.68‐3.87	(m,	3H,	3'‐H	and	2'‐CH2),	4.24	(t,	2H,	J	=	6.1	
Hz,	CH2CH2CH2O),	6.86	(s,	1H,	5‐H),	7.44‐7.55	(m,	3H,	m,p‐Ph),	
8.34‐8.39	 (m,	 2H,	 o‐Ph).	 13C	 NMR	 (75.5	 MHz,	 CDCl3,	 δ,	 ppm):	
26.9,	36.6,	37.1,	38.5,	39.0,	41.4,	51.7,	67.8,	106.9,	128.4,	128.7,	
131.8,	135.8,	164.88,	164.91,	173.1,	174.2.		
	
2.2.8.	Synthesis	of	4‐(2‐phenyl‐6‐(pyrrolidin‐1‐yl)pyrimidin‐
4‐yl)‐1‐(3‐(pyrrolidin‐1‐yl)propyl)pyrrolidin‐2‐one	(14)	
	
To	 a	 solution	 of	 compound	 13	 (300	 mg,	 0.638	 mmol)	 in	
anh.	CH2Cl2	(5	mL)	under	argon	was	added	pyrrolidine	(700	µL,	
8.3	mmol)	 and	 the	mixture	was	 stirred	under	 reflux	 for	 19	h.	
Volatile	 components	 were	 evaporated	 in	 vacuum	 and	 the	
residue	 was	 purified	 by	 FC	 (EtOAc:MeOH:Et3N,	 10:1:1).	
Fractions	 containing	 the	 product	 were	 combined	 and	 volatile	
components	were	evaporated	in	vacuum	to	give	compound	14	
(Scheme	3).	Yield:	60	mg	(22%)	of	colorless	oil.	 1H	NMR	(300	
MHz,	CDCl3,	δ,	ppm):	1.73‐1.90	 (m,	6H,	CH2CH2CH2	and	2×CH2	
of	pyrrolidine),	 1.98‐2.12	 (m,	 4H,	 2×CH2	of	pyrrolidine),	 2.49‐
2.60	(m,	6H,	3×CH2N	of	pyrrolidine),	2.73	(dd,	1H,	J	=	16.7,	9.1	
Hz,	4'‐Ha),	2.90	(dd,	1H,	 J	=	16.7,	7.4	Hz,	4'‐Hb),	3.19‐3.61	(m,	
7H,	3'‐H,	CH2N	of	pyrrolidine,	CH2CH2CH2N,	and	CH2CH2CH2O),	
3.67	(dd,	1H,	J	=	9.7,	6.4	Hz,	2'‐Ha),	3.74	(dd,	1H,	J	=	9.7,	8.7	Hz,	
2'‐Hb),	6.05	 (s,	1H,	5‐H),	7.38‐7.46	 (m,	3H,	m,p‐Ph);	8.39‐8.47	
(m,	2H,	o‐Ph).	 13C	NMR	 (75.5	MHz,	CDCl3,	 δ,	 ppm):	 23.5,	25.4,	
26.6,	37.1,	38.8,	40.8,	46.5,	52.5,	53.7,	54.2,	98.9,	128.3,	128.3,	
130.2,	 138.8,	 160.8,	 163.7,	 167.6,	 174.2.	 ESI:	 m/z	 found	 for	
C25H33N5O:	 m/z	 =	 420.2745	 (MH+);	 calcd.:	 m/z	 =	 420.2763	
(MH+).	
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2.2.9.	Synthesis	of	1‐(3‐hydroxypropyl)‐4‐(2‐phenyl‐6‐
(pyrrolidin‐1‐yl)pyrimidin‐4‐yl)pyrrolidin‐2‐one	(15)	
	
To	a	cooled	(‐5	°C)	solution	of	compound	6g	(471	mg,	1.503	
mmol)	 in	 anh.	 CH2Cl2	 (5	 mL)	 was	 added	 anh.	 Et3N	 (252	 µL,	
1.804	mmol)	followed	by	addition	of	methanesulfonyl	chloride	
(116	µL,	1.503	mmol)	and	the	resulting	mixture	was	stirred	at	‐
5	 °C	 for	20	min.	 and	 then	at	 r.t.	 for	1	h.	The	 reaction	mixture	
was	 directly	 (without	 previous	 evaporation)	 purified	 by	 FC	
(EtOAc).	Fractions	containing	the	intermediate	mono‐mesylate	
were	 combined,	 evaporated	 in	 vacuum,	 and	 the	 residue	 was	
dried	 under	 high	 vacuum	 (r.t./0.1	 Torr).	 The	 residue	 was	
dissolved	in	anhydrous	CH2Cl2	(5	mL)	under	argon	followed	by	
addition	 of	 pyrrolidine	 (253	 µL,	 3	 mmol),	 the	 mixture	 was	
stirred	 at	 r.t.	 for	 two	 days,	 and	 evaporated	 in	 vacuum.	 The	
residue	 was	 purified	 by	 FC	 (EtOAc:MeOH,	 10:1).	 Fractions	
containing	 the	 product	 were	 combined,	 volatile	 components	
were	 evaporated	 in	 vacuo,	 and	 the	 residue	 was	 purified	 by	
MPLC	 (EtOAc:MeOH,	 10:1).	 Fractions	 containing	 the	 product	
were	 combined	 and	 volatile	 components	 were	 evaporated	 in	
vacuum	to	give	compound	15	(Scheme	3).	Yield:	174	mg	(31%)	
of	white	solid.	M.p.:	101‐105	°C	(white	solid).	FT‐IR	(KBr,	cm‐1):	
3406	(CH)	 (alcohol),	 2942	(CH)	 (alkyl),	 2872	(CH)	 (alkyl),	
1668	 (C=O)	 (amide),	 1596,	 1536,	 1505,	 1455,	 1381,	 1347,	
1168,	1062,	1028,	700.	 1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	
1.64	 (p,	 2H,	 J	 =	 6.8	Hz,	 CH2CH2CH2),	 1.97	 (br	 s,	 4H,	 2×CH2	 of	
pyrrolidine),	2.63	(d,	2H,	 J	=	8.1	Hz,	4'‐CH2),	3.21‐3.36	(m,	2H,	
CH2CH2CH2N),	3.36‐3.46	(m,	5H,	2×CH2N	of	pyrrolidine	and	3'‐
H),	 3.50‐3.66	 (m,	 3H,	 CH2CH2CH2O	 and	 2'‐Ha),	 3.73	 (t,	 1H,	 J	 =	
7.5	Hz,	2'‐Hb),	4.43	(br	s,	1H,	OH),	6.35	(s,	1H,	5‐H),	7.43‐7.48	
(m,	3H,	m,p‐Ph),	 8.29‐8.42	 (m,	2H,	o‐Ph).	 13C	NMR	 (75.5	MHz,	
CDCl3,	δ,	ppm):	25.2,	29.6,	36.9,	38.7,	39.0,	46.3,	52.7,	58.5,	98.8,	
128.1,	 128.2,	 130.1,	 138.6,	 160.7,	 163.6,	 167.3,	 175.0.	 HRMS	
(EI):	m/z	 found	for	C21H26N4O2:	m/z	=	367.2122	(MH+);	calcd.:	
m/z	=	367.2134	(MH+).	
	
2.2.10.	Synthesis	of	tert‐butyl	4‐(1‐(3‐(benzyloxy)propyl)‐5‐
oxopyrrolidin‐3‐yl)‐6‐oxo‐2‐phenylpyrimidine‐1(6H)‐
carboxylate	(16)	
To	 a	 solution	 of	 compound	 6f	 (360	mmol	 0.89	mmol)	 in	
anh.	 THF	 (5	 mL)	 was	 added	 Et3N	 (63	 mL,	 0.45	 mmol)	 and	
DMAP	 (56	 mg,	 0.45	 mmol)	 followed	 by	 addition	 of	 (Boc)2O	
(397	mg,	1.78	mmol)	and	the	mixture	was	stirred	at	r.t.	for	3	h.	
The	 reaction	 mixture	 was	 diluted	 with	 EtOAc	 (200	 mL)	 and	
washed	with	water	 (2×50	mL).	 The	 organic	 phase	 was	 dried	
over	anhydrous	Na2SO4,	filtered,	and	volatile	components	were	
evaporated	in	vacuum.	The	residue	was	purified	by	CC	(EtOAc).	
Fractions	 containing	 the	 product	 were	 combined	 and	 volatile	
components	were	evaporated	in	vacuum	to	give	compound	16	
(Scheme	3).	 Yield:	 365	mg	 (81%)	 of	 light	 yellowish	 oil.	 FT‐IR	
(NaCl,	 cm‐1):	 2930	 (CH)	 (alkyl),	 1767	 (C=O)	 (ester),	 1693	
(C=O)	 (amide),	 1590,	 1573,	 1558,	 1494,	 1455,	 1386,	 1246,	
1132,	1057,	852,	698.	1H	NMR	(300	MHz,	CDCl3,	δ,	ppm):	1.60	
(s,	9H,	t‐Bu),	1.90	(dq,	2H,	J	=	7.5,	6.2	Hz,	CH2CH2CH2),	2.73‐2.94	
(m,	2H,	4'‐CH2),	3.48	(t,	2H,	J	=	7.1	Hz,	CH2CH2CH2N),	3.53	(t,	2H,	
J	 =	 6.1	 Hz,	 CH2CH2CH2O),	 3.61‐3.84	 (m,	 3H,	 3'‐H	 and	 2'‐CH2),	
4.46	 (s,	2H,	PhCH2O),	6.93	 (s,	 1H,	5‐H),	7.21‐7.36	 (m,	5H,	Ph),	
7.42‐7.54	 (m,	 3H,	m,p‐Ph),	 8.39‐8.46	 (m,	 2H,	 o‐Ph).	 13C	 NMR	
(CDCl3,	75.5	MHz):	δ	27.8,	27.9,	37.1,	39.1,	40.4,	52.4,	68.0,	73.3,	
85.3,	 107.6,	 127.8,	 128.0,	 128.6,	 128.7,	 131.6,	 136.6,	 138.5,	
149.6,	 165.6,	 165.8,	 173.3.	 HRMS	 (EI):	 m/z	 found	 for	
C29H33N3O5:	 m/z	 =	 504.2478	 (MH+);	 calcd.:	 m/z	 =	 504.2498	
(MH+).	
	
3.	Results	and	discussion		
	
First,	 methyl	 3‐oxo‐3‐(5‐oxo‐1‐phenylpyrrolidin‐3‐yl)	
propanoate	(10a)	was	prepared	in	two	steps	form	itaconic	acid	
(7a)	 following	 the	 literature	procedure	 [16].	Treatment	of	 the	
β‐keto	ester	10a	with	formamidine	acetate	(11a),	acetamidine	
hydrochloride	 (11b),	 benzamidine	 hydrochloride	 (11c),	 [1,1'‐
biphenyl]‐4‐carboxamidine	 hydrochloride	 (11d),	 and	 4‐
((pyrrolidin‐1‐yl)methyl)benzamidine	 dihydrochloride	 (11e)	
in	methanol	in	the	presence	of	potassium	tert‐butoxide	at	room	
temperature	 afforded	 the	 corresponding	 2‐substituted	 6‐(5‐
oxo‐1‐phenylpyrrolidin‐3‐yl)pyrimidin‐4(3H)‐ones	6a‐e	 in	33‐
72%	yields	(Scheme	2).	Next,	we	tried	to	prepare	the	analogues	
of	6a‐e	 bearing	polar	 substituents	 at	 the	pyrrolidine	nitrogen	
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atom	following	the	above	synthetic	route.	Though	treatment	of	
itaconic	 acid	 (7a)	 with	 3‐amino‐1‐propanol	 (8c)	 and	 3‐
(dimethylamino)propanamine	(8d)	 in	water	under	reflux	[18]	
did	 afford	 the	 corresponding	 5‐oxopyrrolidin‐3‐carboxylic	
acids	9c	and	9d,	further	carboxymethylation	under	Masamune‐
Claisen	conditions	did	not	 give	 the	desired	β‐keto	esters.	This	
was	not	really	surprising,	since	carboxylic	acids	bearing	highly	
polar	and/or	basic	substituents	are	usually	difficult	substrates	
for	Masamune‐Claisen	condensations	 [13].	On	 the	other	hand,	
condensation	 of	 dimethyl	 itaconate	 (7b)	 with	 3‐(benzyloxy)	
propylamine	 (8b)	 [19]	 in	 methanol	 at	 room	 temperature	
proceeded	smoothly	to	afford	methyl	1‐(3‐(benzyloxy)propyl)‐
5‐oxopyrrolidine‐3‐carboxylate	 (12)	 in	 quantitative	 yield.	
Hydrolysis	of	the	ester	12	 then	gave	the	carboxylic	acid	9b	 in	
87%	yield.	Quite	 expectedly,	Masamune‐Claisen	homologation	
of	the	carboxylic	acid	9b	with	protected	OH	functionality	at	the	
side	 chain	 led	 to	 the	 corresponding	 β‐keto	 ester	 10b,	 which	
was	 cyclized	 with	 benzamidine	 (11c)	 to	 furnish	 6‐(1‐(3‐
(benzyloxy)propyl)‐5‐oxopyrrolidin‐3‐yl)‐2‐phenylpyrimidin‐
4(3H)‐one	(6f)	in	46%	yield	over	two	steps	(Scheme	2).	
Finally,	 some	 transformations	 and	 derivatizations	 using	
functionalized	 pyrimidinone	 6f	 as	 a	 starting	 material	 were	
carried	out.	Catalytic	hydrogenation	under	3	bar	of	hydrogen	in	
the	presence	of	10%	Pd‐C	resulted	in	removal	of	the	O‐benzyl	
group	to	afford	the	N'‐(3‐hydroxypropyl)‐substituted	analogue	
6g	 in	 60%	 yield.	 Subsequent	 mesylation	 of	 6g	 with	 two	
equivalents	of	mesyl	chloride	at	‐5	°C	→	20	°C	produced	the	bis‐
o‐mesylate	13	in	86%	yield,	while	further	treatment	of	13	with	
excess	 pyrrolidine	 in	 refluxing	 dichloromethane	 for	 19	 h	 did	
not	 proceed	 to	 completion	 and	 furnished	 4‐(2‐phenyl‐6‐
(pyrrolidin‐1‐yl)pyrimidin‐4‐yl)‐1‐(3‐(pyrrolidin‐1‐yl)propyl)	
pyrrolidin‐2‐one	 (14)	 along	 with	 several	 by‐products.	 Upon	
chromatographic	workup,	the	bis‐substitution	product	14	was	
isolated	in	22%	yield.	To	obtain	the	mono‐aminated	compound	
as	well,	the	pyridone	6g	was	treated	first	with	one	equivalent	of	
mesyl	 chloride	 at	 ‐5	 °C	→	 20	 °C	 and	 the	 intermediate	mono‐
mesylate	 was	 treated	 further	 with	 two	 equivalents	 of	
pyrrolidine	 in	dichloromethane	at	room	temperature	 for	48	h.	
Subsequent	 chromatographic	 workup	 afforded	 1‐(3‐
hydroxypropyl)‐4‐(2‐phenyl‐6‐(pyrrolidin‐1‐yl)pyrimidin‐4‐yl)	
pyrrolidin‐2‐one	 (15)	 in	31%	yield.	 It	 is	noteworthy,	 that	 low	
yields	 of	 the	 amination	 products	 14	 and	 15	 were	 due	 to	
incomplete	 conversion	 and	 competitive	 formation	 of	 by‐
products	 upon	 treatment	 of	 the	 mesylates	 with	 excess	
pyrrolidine.	 Further,	 low	 yield	 of	 the	mono‐aminated	 product	
15	 could	 also	 be	 explained	 by	 lack	 of	 chemoselectivity	 in	 the	
mesylation	step,	since	formation	of	the	bis‐mesylate	13	as	the	
by‐product	 was	 detected	 by	 TLC.	 Acylation	 of	 pyrimidone	 6f	
with	 Boc2O	 in	 the	 presence	 of	 4‐dimethylaminopyridine	
(DMAP)	 proceeded	 smoothly	 to	 furnish	 the	 N‐acylated	
pyrimidone	16	in	81%	yield	(Scheme	3).	
The	structures	of	newcompounds	9b,	10b,	6a‐g,	and	12‐16	
were	determined	by	spectroscopic	methods	(1H	NMR,	13C	NMR,	
IR,	 HRMS)	 and	 by	 elemental	 analyses	 for	 C,	 H,	 and	 N.	
Compounds	 9b,	 10b,	 6f,g,	 and	 12‐16	 were	 not	 obtained	 in	
analytically	pure	 form.	Their	 identities	were	confirmed	by	 13C	
NMR	 and	 HRMS.	 Spectral	 data	 for	 compounds	 novel	
compounds	9b,	10b,	6a‐g,	and	12‐16	were	in	agreement	with	
the	 data	 for	 closely	 related	 known	 compounds	 [16,17].	
Structural	 assignment	 of	 1‐(3‐hydroxypropyl)‐4‐(2‐phenyl‐6‐
(pyrrolidin‐1‐yl)pyrimidin‐4‐yl)pyrrolidin‐2‐one	 (15)	 was	
based	 on	 1H	 NMR	 data.	 A	 broad	 singlet	 at	 4.43	 ppm	 was	 in	
agreement	 with	 the	 aliphatic	 OH	 group,	 whereas	 the	
regioisomeric	 6‐(5‐oxo‐1‐(3‐(pyrrolidin‐1‐yl)propyl)pyrroli‐
din‐3‐yl)‐2‐phenylpyrimidin‐4(3H)‐one	should	exhibit	 a	broad	
signal	at	~12	ppm	corresponding	to	the	pyridone	NH	group.		
	
	
	
	
	
4.	Conclusion	
	
In	conclusion,	 s	 simple	 three	 step	synthesis	of	6‐(5‐oxo‐1‐
phenylpyrrolidin‐3‐yl)pyrimidin‐4(3H)‐ones	6a‐f	 from	 comer‐
cially	available	itaconic	acid	(7a)	was	developed.	The	synthesis	
comprises	 cyclisation	 of	 7a	 with	 a	 primary	 amine	 8,	
Masamune‐Claisen	homologation	of	5‐pyrrolidone‐3‐carboxylic	
acid	9,	 and	 cyclisation	 of	 the	 so	 formed	 β‐keto	 ester	with	 an	
amidine	11.	 Unfortunately,	 polar	N‐substituents	 bearing	basic	
or	 acidic	 functional	 groups	 are	 not	 compatible	 with	 the	
Masamune‐Claisen	condensation;	however,	this	problem	can	be	
circumvented	by	suitable	protection	of	these	functional	groups	
or	by	transformation	of	the	N‐substituents	after	the	pyrimidine	
ring	formation.	
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